Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV000584244 | SCV000687415 | likely benign | Hereditary cancer-predisposing syndrome | 2016-05-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001457278 | SCV001661079 | likely benign | Ataxia-telangiectasia syndrome | 2024-12-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000584244 | SCV002750273 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-06-10 | criteria provided, single submitter | clinical testing | The c.2751C>T variant (also known as p.S917S), located in coding exon 17 of the ATM gene, results from a C to T substitution at nucleotide position 2751. This nucleotide substitution does not change the serine at codon 917. This nucleotide position is poorly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will result in the creation or strengthening of a novel splice acceptor site. RNA studies have demonstrated that this alteration results in an incomplete splice defect; the clinical impact of this abnormal splicing is unknown at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Myriad Genetics, |
RCV004592467 | SCV005085054 | benign | Familial cancer of breast | 2024-05-10 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |